Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Riccardo Asteggiano,
The great advances in chemotherapy have led to a significant improvement of cancer prognosis but have dramatically increased the incidence of cardiotoxicity.At present, the secondary effects of cancer therapy that have been shown, of which some are potentially reversible (type II agents – mainly signalling inhibitors), others stable (type I agents – cytotoxic agents) and arising also after many years, are as follows: left ventricular dysfunction, hypertension, arrhythmias (acquired LQTs), myocardial ischemia and thrombotic manifestations.The aim of this session was to enhance the knowledge of all cardiologists, even if not specifically trained in the field, on the general principle of cardiotoxicity from cancer therapy, the specific clinical implications, and the management criteria.This could be a difficult task considering the rapidly growing number of new agents used in chemotherapy and the lack of large randomized trials. It is time to simplify the approach to the problem using a schematization of current knowledge, and to permit a rapid update of the new information.Moreover, it is mandatory to know:
Chemotherapy and the heart: what the cardiologist must know
© 2017 European Society of Cardiology. All rights reserved